A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

BACKGROUND Limited data are available regarding global hepatitis B virus (HBV)-related morbidity and mortality and potential reduction in disease burden from hepatitis B vaccination. METHODS A model was developed to calculate the age-specific risk of acquiring HBV infection, acute hepatitis B (illness and death), and progression to chronic HBV infection. HBV-related deaths among chronically infected persons were determined from HBV-related cirrhosis and hepatocellular carcinoma (HCC) mortality curves, adjusted for background mortality. The effect of hepatitis B vaccination was calculated from vaccine efficacy and vaccination series coverage, with and without administration of the first dose of vaccine within 24 h of birth (i.e. birth dose) to prevent perinatal HBV infection. RESULTS For the year 2000, the model estimated 620,000 persons died worldwide from HBV-related causes: 580,000 (94%) from chronic infection-related cirrhosis and HCC and 40,000 (6%) from acute hepatitis B. In the surviving birth cohort for the year 2000, the model estimated that without vaccination, 64.8 million would become HBV-infected and 1.4 million would die from HBV-related disease. Infections acquired during the perinatal period, in early childhood (<5 years old), and > or = 5 years of age accounted for 21, 48, and 31% of deaths, respectively. Routine infant hepatitis B vaccination, with 90% coverage and the first dose administered at birth would prevent 84% of global HBV-related deaths. CONCLUSION Globally, most HBV-related deaths result from the chronic sequelae of infection acquired in the perinatal and early childhood periods. Inclusion of hepatitis B vaccine into national infant immunization programs could prevent >80% of HBV-related deaths.

[1]  Ding Zg.  [Epidemiological study on relationship between hepatitis B and liver cancer--a prospective study on development of liver cancer and distribution of HBsAg carriers and liver damage persons in Guangxi] , 1988 .

[2]  B. McMahon,et al.  Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. , 1990, Archives of internal medicine.

[3]  T R Bender,et al.  Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.

[4]  H. Margolis,et al.  Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up , 2005, Annals of Internal Medicine.

[5]  B. Yvonnet,et al.  Persistent hepatitis B virus infection and hepatoma in The Gambia, west Africa. A case-control study of 140 adults and their 603 family contacts. , 1992, American journal of epidemiology.

[6]  Sun,et al.  Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: a population-based case-control study in Taiwan. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  J. Ferlay,et al.  Cancer and infection: estimates of the attributable fraction in 1990. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  P E Fine,et al.  Herd immunity: history, theory, practice. , 1993, Epidemiologic reviews.

[9]  H. Margolis,et al.  Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. , 1985, Pediatrics.

[10]  European Consensus Group on Hepatitis B Immunity.  Are booster immunisations needed for lifelong hepatitis B immunity? , 2000, The Lancet.

[11]  Ruth E. Brown,et al.  Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. , 1995, JAMA.

[12]  K. Eguchi,et al.  Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan , 2000, Journal of Gastroenterology.

[13]  Hui Li,et al.  Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. , 1999, Vaccine.

[14]  J. Tsai,et al.  Hepatitis C virus infection as a risk factor for non‐alcoholic liver cirrhosis in taiwan , 1993, Journal of medical virology.

[15]  L. Hwang,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 1984, Seminars in liver disease.

[16]  F. André.  Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. , 1989, The American journal of medicine.

[17]  R. Beasley,et al.  Vertical transmission of hepatitis B antigen in Taiwan. , 1975, The New England journal of medicine.

[18]  F Meehan,et al.  Shaping the future. , 1991, Nursing.

[19]  G. Karvountzis,et al.  Long Term Follow-Up Studies of Patients Surviving Fulminant Viral Hepatitis , 1974 .

[20]  N. Unwin,et al.  Cause-specific adult mortality: evidence from community-based surveillance--selected sites, Tanzania, 1992-1998. , 2000, MMWR. Morbidity and mortality weekly report.

[21]  W. M. Lee,et al.  Hepatitis B virus infection. , 1997, The New England journal of medicine.

[22]  H. Margolis,et al.  Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. , 2000, The Journal of infectious diseases.

[23]  Y. Ko,et al.  Incidence of hepatitis among students at a university in Taiwan. , 1983, American journal of epidemiology.

[24]  F. Hsieh,et al.  Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized Double‐Blind, Placebo‐Controlled Trial , 2007, Hepatology.

[25]  H. Inskip,et al.  Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: factors influencing antibody response. , 1991, International journal of epidemiology.

[26]  M. Yuen,et al.  Twelve‐year follow‐up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma‐derived vaccine without booster doses in children , 1999, Hepatology.

[27]  W. Szmuness,et al.  HBeAg and anti‐hbe detection by radioimmunoassay: Correlation with vertical transmission of hepatitis B virus in Taiwan , 1979, Journal of medical virology.

[28]  P. Beutels.  Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). , 2001, Health economics.

[29]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[30]  John Paxton,et al.  Republic of China , 1978 .

[31]  H. Margolis,et al.  Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. , 1999, American journal of public health.

[32]  C. Siu,et al.  HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects , 2004, Hepatology.

[33]  H. Whittle,et al.  Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children , 2002, BMJ : British Medical Journal.

[34]  B. McMahon,et al.  Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus , 2001, Annals of Internal Medicine.

[35]  S. Hadziyannis.  REVIEW: Hepatitis delta , 1997, Journal of gastroenterology and hepatology.

[36]  D. Alagille,et al.  SEVERE VIRAL HEPATITIS TYPE B IN INFANCY , 1975, The Lancet.

[37]  N. Tabibian.  Hepatocellular carcinoma in the United States. , 1988, American family physician.

[38]  K. Hyams.  Risks of chronicity following acute hepatitis B virus infection: a review. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  W. Szmuness,et al.  Incidence of hepatitis B virus infections in preschool children in Taiwan. , 1982, The Journal of infectious diseases.

[40]  Dr. Chau Tai-Nin,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 2006 .

[41]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[42]  Mei-Hwei Chang,et al.  Long‐term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen , 1999, Hepatology.

[43]  R. Jenkins,et al.  Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival , 1996, Cancer.

[44]  B. Yvonnet,et al.  Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. , 1994, Journal of hepatology.

[45]  J. Hoofnagle,et al.  Viral hepatitis and liver disease , 1984 .

[46]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[47]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[48]  M. Imai,et al.  e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. , 1976, The New England journal of medicine.

[49]  J. Tsai,et al.  Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. , 1996, British Journal of Cancer.

[50]  L. Hwang,et al.  Hepatitis B vaccination in high-risk infants: 10-year follow-up. , 1999, The Journal of infectious diseases.

[51]  A. Zanetti,et al.  Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. , 2001, The Journal of infectious diseases.

[52]  C E Stevens,et al.  The e antigen and vertical transmission of hepatitis B surface antigen. , 1977, American journal of epidemiology.

[53]  M. Birmingham,et al.  Global Progress Toward Universal Childhood Hepatitis B Vaccination, 2003 , 2003, MMWR. Morbidity and mortality weekly report.

[54]  Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). , 1991, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[55]  A J Hall,et al.  The influence of age on the development of the hepatitis B carrier state , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[56]  T. Frieden,et al.  Chronic liver disease in central harlem: The role of alcohol and viral hepatitis , 1999, Hepatology.

[57]  G. Meucci,et al.  The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers , 1993, Annals of Internal Medicine.

[58]  J. Goedert,et al.  The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa , 2004, Hepatology.

[59]  Chien-Lin Chen,et al.  Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: Sixteen years after newborn vaccination program in Taiwan , 2003, Journal of medical virology.

[60]  K. Böker,et al.  Akutes Leberversagen , 2001, Der Internist.